Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOS NASDAQ:LFCR NASDAQ:TELO NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.56+3.6%$2.78$0.97▼$3.60$178.40M0.32320,192 shs162,659 shsLFCRLifecore Biomedical$4.79+0.4%$5.19$3.63▼$8.98$178.92M1.08239,398 shs202,697 shsTELOTelomir Pharmaceuticals$1.30-1.5%$1.33$1.05▼$3.10$45.38M-0.21243,396 shs70,808 shsTLSATiziana Life Sciences$1.58+4.6%$1.31$1.14▼$2.60$192.16M0.42171,995 shs167,868 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+3.35%-4.26%+2.92%+147.92%LFCRLifecore Biomedical0.00%-5.92%+12.50%-36.99%-31.81%TELOTelomir Pharmaceuticals0.00%-5.71%-0.75%+14.78%-46.99%TLSATiziana Life Sciences0.00%+17.97%+18.90%+11.03%-3.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$2.56+3.6%$2.78$0.97▼$3.60$178.40M0.32320,192 shs162,659 shsLFCRLifecore Biomedical$4.79+0.4%$5.19$3.63▼$8.98$178.92M1.08239,398 shs202,697 shsTELOTelomir Pharmaceuticals$1.30-1.5%$1.33$1.05▼$3.10$45.38M-0.21243,396 shs70,808 shsTLSATiziana Life Sciences$1.58+4.6%$1.31$1.14▼$2.60$192.16M0.42171,995 shs167,868 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%+3.35%-4.26%+2.92%+147.92%LFCRLifecore Biomedical0.00%-5.92%+12.50%-36.99%-31.81%TELOTelomir Pharmaceuticals0.00%-5.71%-0.75%+14.78%-46.99%TLSATiziana Life Sciences0.00%+17.97%+18.90%+11.03%-3.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 2.50Moderate Buy$6.67160.42% UpsideLFCRLifecore Biomedical 2.20Hold$6.0025.26% UpsideTELOTelomir Pharmaceuticals 2.00HoldN/AN/ATLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TELO, TLSA, LFCR, and ABOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026LFCRLifecore Biomedical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/6/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026LFCRLifecore Biomedical Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.50 ➝ $6.004/21/2026LFCRLifecore Biomedical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/21/2026TELOTelomir Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026ABOSAcumen Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026ABOSAcumen Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/24/2026LFCRLifecore Biomedical Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$5.503/18/2026TELOTelomir Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/17/2026LFCRLifecore Biomedical Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$5.503/16/2026ABOSAcumen Pharmaceuticals BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$1.16 per shareN/ALFCRLifecore Biomedical$128.87M1.39N/AN/A($0.76) per share-6.30TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.17 per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$121.33M-$2.01N/AN/AN/AN/A-111.26%-75.67%5/12/2026 (Estimated)LFCRLifecore BiomedicalN/A-$0.98N/AN/AN/A-25.43%-1,211.09%-14.40%N/ATELOTelomir Pharmaceuticals-$10.41M-$0.33N/AN/AN/AN/A-315.26%-259.29%5/13/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/A6/18/2026 (Estimated)Latest TELO, TLSA, LFCR, and ABOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026N/ATELOTelomir Pharmaceuticals-$0.07N/AN/AN/AN/AN/A5/12/2026Q1 2026ABOSAcumen Pharmaceuticals-$0.4028N/AN/AN/AN/AN/A5/6/2026Q1 2026LFCRLifecore Biomedical-$0.29-$0.43-$0.14-$0.43$25.96 million$23.19 million5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/A3/26/2026Q4 2025ABOSAcumen Pharmaceuticals-$0.50-$0.41+$0.09-$0.41N/A($0.09) million3/17/2026Q4 2025TELOTelomir Pharmaceuticals-$0.07-$0.06+$0.01-$0.06N/AN/A3/16/2026Transition periodLFCRLifecore Biomedical-$0.11-$0.16-$0.05-$0.16$35.31 million$35.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.324.074.07LFCRLifecore BiomedicalN/A3.791.67TELOTelomir PharmaceuticalsN/A5.145.14TLSATiziana Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%LFCRLifecore Biomedical83.36%TELOTelomir PharmaceuticalsN/ATLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%LFCRLifecore Biomedical32.68%TELOTelomir PharmaceuticalsN/ATLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2072.23 million65.51 millionOptionableLFCRLifecore Biomedical69037.51 million25.23 millionOptionableTELOTelomir Pharmaceuticals134.38 millionN/AN/ATLSATiziana Life Sciences8127.26 million76.58 millionOptionableTELO, TLSA, LFCR, and ABOS HeadlinesRecent News About These CompaniesTiziana Life Sciences Delays Annual 20-F FilingMay 2, 2026 | theglobeandmail.comWall Street Zen Downgrades Tiziana Life Sciences (NASDAQ:TLSA) to SellApril 18, 2026 | marketbeat.comTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and ...April 17, 2026 | finanznachrichten.deTiziana says intranasal drug shows potential to ease Long COVID “brain fog”April 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionApril 16, 2026 | globenewswire.comTiziana Life Sciences to present Phase 2a MSA study at World Parkinson CongressApril 14, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressApril 14, 2026 | globenewswire.comTiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingApril 1, 2026 | uk.finance.yahoo.comTiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain agingApril 1, 2026 | proactiveinvestors.comTiziana reports biomarker gains for nasal MS therapy in progressive diseaseFebruary 25, 2026 | proactiveinvestors.comTiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRAFebruary 25, 2026 | globenewswire.comWhile insiders own 43% of Tiziana Life Sciences Ltd (NASDAQ:TLSA), individual investors are its largest shareholders with 53% ownershipFebruary 9, 2026 | finance.yahoo.comTiziana Life Sciences publishes positive study on intranasal MS therapyJanuary 20, 2026 | proactiveinvestors.comTiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal ForalumabJanuary 20, 2026 | globenewswire.comTiziana Life Sciences announces closing of oversubscribed $8.8M offeringJanuary 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary SharesJanuary 16, 2026 | globenewswire.comTiziana Life Sciences unveils registered direct offering of up to $17.6MJanuary 16, 2026 | proactiveinvestors.comTiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 MillionJanuary 16, 2026 | globenewswire.comTiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San FranciscoJanuary 9, 2026 | globenewswire.comTiziana Life Sciences submits annual safety report for intranasal foralumab to FDADecember 29, 2025 | proactiveinvestors.comTiziana Files Annual Safety Report for Intranasal Foralumab with FDADecember 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20263 Reasons Analysts Love DexComBy Nathan Reiff | May 5, 2026TELO, TLSA, LFCR, and ABOS Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$2.56 +0.09 (+3.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.60 +0.04 (+1.52%) As of 05/8/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Lifecore Biomedical NASDAQ:LFCR$4.79 +0.02 (+0.42%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.78 0.00 (-0.10%) As of 05/8/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Telomir Pharmaceuticals NASDAQ:TELO$1.30 -0.02 (-1.52%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.34 +0.04 (+3.38%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Tiziana Life Sciences NASDAQ:TLSA$1.58 +0.07 (+4.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.56 -0.02 (-1.52%) As of 05/8/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
